Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Western Galilee Hospital-Nahariya.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Rambam Health Care Campus
Information provided by:
Western Galilee Hospital-Nahariya
ClinicalTrials.gov Identifier:
NCT01018719
First received: November 17, 2009
Last updated: November 23, 2009
Last verified: November 2009

November 17, 2009
November 23, 2009
January 2010
December 2011   (final data collection date for primary outcome measure)
Degree of damage to the coronary arteries as measured by MDCT [ Time Frame: 5 to 15 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01018719 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)
Evaluation of Radiation Induced Cardiotoxicity by Multi-detector Computed Tomography (MDCT)

The current study is aimed to evaluate various imaging methods, including multidetector computed tomography (MDCT) as potential surrogates to assess the degree of damage caused to the heart by radiation therapy to the breast, in breast cancer survivors many years before it becomes clinically apparent.

Early detection and improved treatment approaches following breast cancer (BC) have increased disease specific survival and resulted in increasing cohorts of BC survivors who are prone to develop late complications from treatment, including damage caused by radiation therapy (RT) to the heart. Older RT techniques for treating the breast resulted in excess cardiovascular morbidity and mortality. Improved RT techniques minimize irradiation to the heart. Data from various trials have yielded conflicting results on the extent to which these contemporary techniques have actually decreased cardiotoxicity. Long term follow-up and large cohorts are needed in order to evaluate the risk for cardiotoxicity, when based on its clinical manifestations. The current study is aimed to evaluate various imaging methods as potential surrogates to assess the degree of damage caused to the heart by RT in BC survivors many years before it becomes clinically apparent.This includes Multi-detector computed tomography (MDCT) - based on high resolution computed tomography of the heart following injection of contrast medium which evaluates the degree of stenosis of the coronary arteries.

One hundred patients treated for breast carcinoma, fifty with left breast and fifty with right breast cancer, will be included in the current study and compared for the incidence of cardiac damage. Since the radiation dose to the heart is substantially lower in patients irradiated for right-sided tumors, comparing the incidence of findings indicating cardiac injury in the two groups will define the contribution of RT to these findings. For each patient included in the study, the incidence of cardiovascular disease will be correlated also with the volume of heart irradiated, the radiation dose delivered to that volume, the concomitant administration of cardiotoxic systemic agents, as well as to patient's age when irradiated and risk factors for developing coronary artery disease.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Patients with breast cancer followed in the oncology clinic.

Breast Cancer
Device: MDCT, ECG, Echocardiography
Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
  • Left side breast cancer
    Intervention: Device: MDCT, ECG, Echocardiography
  • Right side breast cancer
    Intervention: Device: MDCT, ECG, Echocardiography
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
100
Not Provided
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients who were diagnosed with early breast cancer, histologically proven. Both invasive and non invasive histologies will be included.
  2. The study will include patients, who underwent a definitive surgery - either breast conserving or mastectomy - and received radiation therapy to the breast or to the chest wall respectively +/- to lymphatic drainage.
  3. No evidence of recurrence of their malignancy or any other malignant disease.
  4. Age at diagnosis and radiation to the breast will not exceed 60 years.
  5. Signed informed consent by the patient will be mandatory.

Exclusion Criteria:

  1. As MDCT requires injection of contrast media, Patients with contra indications for injection of contrast media, due to either a history of allergic reaction or renal insufficiency, will be excluded of the study.
Female
18 Years to 60 Years
No
Contact: Hadassah Goldberg, MD 972-4-9103482 hadassah.goldberg@naharia.health.gov.il
Contact: Moshe Goldfeld, MD 972-4-9107563 moshe.goldfeld@naharia.health.gov.il
Not Provided
 
NCT01018719
cardiotoxicity66809
No
Dr. Hadassah Goldberg, Director oncology unit, oncology unit, Western Galilee Hospital, Nahariya, Israel
Western Galilee Hospital-Nahariya
Rambam Health Care Campus
Principal Investigator: Hadassah Goldberg, MD Oncology center, Western Galilee Hospital
Western Galilee Hospital-Nahariya
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP